– D-2570 demonstrates robust efficacy and favorable safety profile, achieving skin clearance comparable to leading biologics – SHANGHAI, Dec. 3, 2024 /PRNewswire/ — InventisBio Co., Ltd. today announced promising results from a Phase 2 clinical trial of D-2570, an oral selective…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.